Press Release Details

Eiger Updates on 2019 Progress and 2020 Milestones Expected

- Progeria Rolling NDA Planned for Completion in 1Q 2020
- HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020
- Commercial Focus on Progeria Launch Preparation and HDV Market Building
- Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020

PALO ALTO, Calif., Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today updated on progress across its product pipeline, including clinical and regulatory program planned milestones, and commercial preparation.

Eiger BioPharmaceuticals (PRNewsFoto/Eiger BioPharmaceuticals, Inc.)

Lonafarnib in Progeria and Progeroid Laminopathies

  • Rolling New Drug Application (NDA) with FDA initiated in December 2019
  • Rolling NDA submission planned to complete in 1Q 2020
  • Marketing Authorization Application (MAA) planned to EMA in 1Q 2020
  • Commercial launch preparation underway

Lonafarnib in Hepatitis Delta Virus (HDV) Phase 3 D-LIVR Study

  • Lonafarnib is the only oral agent in development for HDV
  • Over 80 global sites activated in 2019
  • Strategic geographic and high enrolling sites activating early in 2020
  • Enrollment planned to complete in 2020
  • Topline data planned in 2021

Peginterferon Lambda (Lambda) in HDV

  • Positive Phase 2 LIFT (Lambda combo) interim end-of-treatment results reported
    • 53% of patients with HDV RNA BLOQ at Week 24
    • 36% of patients with HDV RNA undetectable at Week 24
  • End of Phase 2 meeting for Lambda monotherapy planned with FDA in 1Q 2020
  • Additional Phase 2 LIFT data expected at EASL and AASLD 2020

Avexitide in Post-Bariatric Hypoglycemia (PBH) and Congenital Hyperinsulinism (CHI)

  • Positive End of Phase 2 meeting with FDA for Avexitide in PBH in 2019
  • Avexitide PBH Phase 3 study design guidance finalized with FDA
  • Assessing strategic options to advance Avexitide in PBH and CHI

"Eiger begins 2020 with four late-stage, FDA Breakthrough Therapy Designation Programs, with first-in-class therapies, targeting rare and ultra-rare diseases with high unmet medical needs with no approved treatments," said David Cory, President and CEO of Eiger.  "We are focused on commercial preparation for an anticipated approval of Lonafarnib in Progeria and Progeroid Laminopathies in 2020 and HDV market development as we prepare for Phase 3 data from our D-LIVR trial in 2021."

Financial Guidance
At December 31, 2019, the Company had approximately $95M in cash, cash equivalents and investments.  The company expects 2020 cash burn for planned operations to be generally in-line with 2019 burn.

About Eiger
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist. 

Eiger has initiated a rolling New Drug Application (NDA) submission process for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.  The company's lead program is in Phase 3, developing lonafarnib, a first-in-class oral prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is also advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV.  For additional information about Eiger and its clinical programs, please visit

Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that involve substantial risks and uncertainties.  All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward-looking statements.  These forward-looking statements include terminology such as "believe," "will," "may," "estimate," "continue," "anticipate," "contemplate," "intend," "target," "project," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms.  Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical development, including planned completion of a rolling NDA submission by first quarter 2020, followed by submission of an MAA in first quarter 2020 for lonafarnib in Progeria and Progeroid Laminopathies; our progression and enrollment of our Phase 3 D-LIVR study in HDV; our planned advancement of Lambda and lonafarnib boosted with ritonavir for HDV; our plans to hold an end of Phase 2 meeting for Lambda in HDV in first quarter 2020; our plans for continued advancement of avexitide; our ability to transition into a commercial stage biopharmaceutical company; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates.  These statements concern product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA).  No representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and Eiger's subsequent filings with the SEC.  Eiger does not assume any obligation to update any forward-looking statements, except as required by law.

Investors: Ingrid Choong, PhD
Email: [email protected] 
Phone: 1-650-619-6115


Cision View original content to download multimedia:

SOURCE Eiger BioPharmaceuticals, Inc.